Global Cancer Tumor Profiling Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|癌症腫瘤分析的全球市場:2020年∼2027年 Global Cancer Tumor Profiling Market - 2020-2027|
|出版日期: 2021年05月10日||內容資訊: 英文 180 Pages||
The Global Cancer Tumor Profiling Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Cancer is generally the proliferation of uncontrolled cell growth, which could be fatal. Environmental reasons mainly cause altering a gene encoding, which triggers cell regulation, and the cell mutation leads to uncontrolled cell growth, which affects the neighboring cells and organs. Cancer tumor profiling provides information about the genes causing cancer, which would offer valuable insights related to the mechanism of cancer. The potential of cancer profiling is limited to common cancers, such as lymphoma and breast cancer, and is helpful in molecular profiling of lung cancer, prostate cancer, and acute leukemia. Cancer profiling has played a vital role in diagnosis at the molecular level, as a better understanding of the cancer tumors helps physicians make appropriate therapeutic decisions and avoid "over-treatment" of the cancer patients.
The global Cancer Tumor Profiling market growth is driven by the growing incidence of Cancer cases, Raising funds in research and development activities aimed at improving the overall course of diagnosis and treatment of the disease and growing technological advancements recently observed in tumor profiling, increasing acceptance of point of care diagnostics and the rise in demand for personalized medicines.
Growing incidence of cancer cases globally, is expected to drive the global Cancer Tumor Profiling market growth.
As per the World Health Organization (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Additionally, according to International Agency for Research on Cancer (IARC) estimates, by 2040, global cancer cases are expected to grow to 27.5 million new cancer cases worldwide. This number has led to an increase in the adoption of various tumor profiling methods.
Technical issues in sample collection and storage conditions are likely hindering the global cancer tumor profiling market
Sample collection is one of the major issues faced by service providers, followed by access to these samples. Stringent quality control of these samples is required, and they need to be stored under the proper conditions to avoid any loss.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the Personalized Cancer Vaccines. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.
Based on the Cancer Type, the global Cancer Tumor Profiling market is segmented into Breast Cancer, Lung cancer, Prostate cancer, Colorectal cancer, Melanoma cancer and Others
The Lung cancer segment is expected to grow at the fastest CAGR during the forecast period (2020-2027).
The increasing prevalence of lung cancer worldwide and the rising need for early diagnosis support this segment's major growth. Lung cancer (both small and non-small cells) is the second most common cancer in both men and women. Most lung cancer statistics include small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In general, about 13% of all lung cancers are SCLC, and 84% are NSCLC. As per the American Cancer Society's estimates for lung cancer in the United States for 2021 are about 235,760 new cases of lung cancer (119,100 in men and 116,660 in women). These factors increasing the global Cancer Tumor Profiling market growth.
Based on the Technology Type, the global Cancer Tumor Profiling market is segmented into Immunoassay, Next-generation Sequencing, Polymerase chain reaction, In-Situ Hybridization, Microarray
The immunoassays segment accounted for the largest market share. The immunoassays are used as a gold standard to conduct tumor profiling on a large scale because they help measure the presence and concentration of analytes in a sample, and these tests are used for tumor diagnosis, prognosis, and also treatment decisions. Moreover, the information gained by conducting these tests in clinical settings helps to shorten hospital stay period and decrease the severity of illnesses by identifying and assessing the progression of the disease, leading to improved therapeutic choices. The high sensitivity and cost-effectiveness of these techniques and technological improvements in these immunoassays tests are some factors expected to drive the growth of this market during the forecast period. For instance, On June 1, 2021, Nantes University Hospital, in collaboration with Roche Diagnostics developing a study that aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in the case of postmenopausal bleedings.
Based on the Biomarker Type, the global Cancer Tumor Profiling market is segmented into Genomic biomarker and Protein biomarker.
The large share of the genomics segment can be attributed to the high adoption of these biomarkers during cancer diagnosis and prognosis and the biomarker discovery process. Genomics plays a vital role in the detection of these genetic variations in cases of reoccurrence. These genomic platforms have proven advantageous as they lead to cost savings, improve screening time, and help identify a larger size of the evaluated genome. These factors are likely to encourage the usage of genomics sciences for tumor profiling in the coming years. For instance, Lucence Health Inc, in 2021, started developing Liquid Biopsy technology for the detection of Actionable Genomic Biomarkers in Patients with Advanced Non-small Cell Lung Cancer (NSCLC).
Based on the application, the global cancer tumor profiling market is segmented into Research, Diagnostics, Personalized medicines and clinical applications.
The research applications segment expected the largest share of cancer/tumor profiling market in the forecast period. The large share of this segment is attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the growing funding for cancer research is propelling the growth of the market.
North America region holds the largest market share global Cancer Tumor Profiling market
North America holds the largest market in the global cancer stem cells market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Molecular Profiling in Small Cell Lung Cancer by Zhujiang Hospital is estimated to complete by September 2021.
The Global Cancer Tumor Profiling Market is quite competitive with some key competitors like Illumina, Inc, QIAGEN N.V, NeoGenomics Laboratories, Genomic Health Inc, Caris Life Sciences, Helomics Corporation, NanoString Technologies, Inc, Sysmex Corporation, Ribomed Biotechnologies, Inc, Roche Diagnostics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, in 2018, Illumina Inc acquired Edico Genome, a leading provider of data analysis acceleration solutions for next generation sequencing (NGS), to accelerate genomic data analysis.
Overview: Illumina is an American company incorporated in 1998. Its headquarters are located in San Diego, California. It is a molecular diagnostics company engaged in the development, manufacturing, and marketing of integrated systems for the analysis of genetic variations and biological functions. The company offers a wide range of integrated sequencing and microarray systems, consumables, and analysis tools to accelerate and simplify genetic analysis.
Product Portfolio: The company operates under two divisions-Product Revenue and Services & Other Revenue. The Product Revenue unit consists of consumables and instruments revenue, while the Services and Other Revenue unit consists of sequencing, genotyping, and instrument service contract revenue.
In 2020, Illumina's COVID response: Illumina partnered with ID by DNA Partner to deliver NGS Infectious Disease solutions. The partnership aims to accelerate Next-generation sequencing adoption of clinical infectious disease testing. This partnership also aims to make next-generation software with powerful bioinformatics software that can turn data into actionable insights.
The global Cancer Tumor Profiling market report would provide an access to an approx. market data 61 tables, 55 figures and 240 pages.
LIST NOT EXHAUSTIVE